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Abstract: Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that produces 
cognitive impairments that increase in severity as the disease progresses. The clinical symp-
toms are related to the presence of neuritic plaques and neuroﬁ  brillary tangles in the cerebral 
cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of 
the disease can result in clinical burden for the patient, emotional strain for those that care for 
patients with Alzheimer’s, and signiﬁ  cant ﬁ  nancial burden to society. The goals of current treat-
ments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to 
reduce the severity or slow the progression of cognitive symptoms. Although these treatments 
have demonstrated modest clinical beneﬁ  t, they are unable to prevent, prohibit, or reverse the 
underlying pathophysiology of AD. Considerable progress has been made toward the develop-
ment of disease-modifying treatments. Treatments currently under development mainly target 
the production, aggregation, and removal of existing amyloid β-peptide aggregates which are 
believed to instigate the overall development of the neuropathology. Additional strategies that 
target tau pathology are being studied to promote neural protection against AD pathology. The 
current research has continued to expand our knowledge toward the development of disease 
modifying Alzheimer’s therapies; however, no speciﬁ  c treatment strategy capable of demon-
strating empirical efﬁ  cacy and safety has yet to emerge.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized 
by a gradual onset and slow progression of cognitive difﬁ  culties. The clinical and 
physiological pathology associated with this illness was ﬁ  rst documented by the neu-
ropathologist, Dr. Alois Alzheimer in 1907. AD represents the most common form of 
dementia syndrome (Fratiglioni et al 2000), which, according to data analyzed from the 
US Census 2000, affects an estimated 4.5 million people in the Unites States (Hebert 
et al 2003). The age groups that have the highest number of individuals with a diagnosis 
of AD are those 75 to 84 years of age and those 85 or older, with prevalence rates of 
2.4 million (53%) and 1.8 million (40%), respectively. Because of the estimated increase 
in people reaching the 75 to 84 and 85 or older age groups, the number of individuals 
diagnosed with AD is projected to increase to 13.2 million by the year 2050.
Caring for patients with AD can create a ﬁ  nancial burden to both society and 
caregivers. The overall cost of AD to the US economy is estimated to be greater than 
$141 billion annually, with an individual patient cost of approximately $35,000 per 
year (Ernst et al 1997). In addition to the monetary cost associated with the illness, 
caregivers of AD patients also experience signiﬁ  cant emotional distress (Donaldson 
et al 1998; Rymer et al 2002). As the disease progresses and the patient becomes more 
debilitated, the amount of time spent caring for the patient will also increase, resulting 
in additional burden on the caregiver.Neuropsychiatric Disease and Treatment 2008:4(4) 766
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The clinical symptoms that are used to diagnose AD 
manifest gradually, and are difﬁ  cult to identify in the early 
stages of the illness. The ﬁ  rst symptoms typically reported 
involve difﬁ  culty with memory, such as the inability to 
recall or learn new information (Greene et al 1996; Salmon 
et al 2002). Patients may forget appointments and recent 
conversations, or even get lost while driving (Lipton and 
Weiner 2003). The memory impairment associated with AD 
will continue to increase as the illness progresses, eventually 
affecting well established, crystallized information such as 
the name of a spouse or children (Yaari and Corey-Bloom 
2007). Difﬁ  culties with language will also become apparent 
through word ﬁ  nding and naming difﬁ  culties, and a gradual 
decrease in proper conversations will eventually occur 
(Vuorinen et al 2000; Blair et al 2007). As with memory and 
language impairments, executive dysfunction will appear, 
resulting in a reduction of a patient’s ability to complete 
complex daily activities (Husain and Garrett 2007). This can 
further increase caregiver burden, as they may be required 
to take over various responsibilities that were previously 
handled by the patient. More importantly, the loss of execu-
tive functioning also increases the need for continual moni-
toring and supervision of these patients due to their limited 
ability to reason, problem solve, and make decisions (Yaari 
and Corey-Bloom 2007). Eventually, patients with AD will 
lose the ability or awareness to perform various basic activi-
ties associated with daily living such as eating, grooming, or 
other hygiene related tasks (Galasko et al 2005).
Changes in mood are commonly reported features of 
AD and continue throughout the illness course. Mega and 
colleagues (1996) reported that apathy is the most com-
mon psychiatric feature of AD (72%), followed by aggres-
sion/agitation (60%), anxiety (48%) and depression (48%). 
The occurrence of apathy may be related to the decrease in 
executive function, which may result in an inability to initiate 
new activities. The more severe behavioral disturbances of 
psychosis and agitation typically occur in the later stages of 
the disease and can be difﬁ  cult to manage.
The neuropathology of AD is characterized by gross brain 
changes and cortical atrophy that has been found to occur 
predominantly in the outer three layers of the cerebral cortex, 
and initially affects the temporal and frontal cortices (Masters 
et al 2006). The pathological hallmarks of AD are the pres-
ence of neuritic plaques and neuroﬁ  brillary tangles, which 
are related to the mass cellular degeneration and neuronal 
death found in various regions of the brain.
Understanding the process in which neuritic plaques and 
neuroﬁ  brillary tangles form is important when developing 
effective treatments for AD. Extracellular neuritic plaques 
present in AD are an aggregation of amyloid β-peptides (Aβ), 
which consist of 40–42 amino acids (Masters et al 2006). As 
these extracellular Aβ peptides or monomers accumulate they 
form neuritic plaques. The neurotoxicity of these plaques 
cause damage to the membranes of axons and dendrites, 
eventually leading to widespread cortical atrophy (Lorenzo 
et al 2000). This buildup of Aβ has also been suggested to be 
the main inciting factor for the manifestation and continual 
progression of AD, as well as the development of the neu-
roﬁ  brillary tangles, which represents the other pathological 
hallmark of AD (Hardy and Selkoe 2002).
Neuroﬁ  brillary tangles are composed of paired heli-
cal ﬁ  laments of abnormally hyperphorylated tau proteins 
(Masters et al 2006). Within healthy neurons, tau proteins 
provide structural support for microtubules which are used to 
send nutrients from the cell body to other regions of the cell. 
The tau proteins seen in AD become hyperphosphorylated 
causing them to aggregate and form tangles within neuronal 
cells (Lovestone and Reynolds1997). As this occurs, the 
microtubules are unable to maintain their structure, and 
thus begin to disintegrate, causing cytoskeletal degenera-
tion which consequently leads to neuronal death. Although 
other forms of dementia are found to have cortical atrophy or 
massive neuronal death, the presences of β-amyloid plaques 
and neuroﬁ  brillary tangles are exclusive pathophysiology of 
AD, and are believed to accumulate for many years before 
the onset of memory impairment.
The current method of diagnosing AD in a clinical setting 
involves obtaining a detailed clinical history, which is used 
to determine whether the patient meets certain characteristics 
of AD and to rule out other forms of dementia. Criteria from 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-TR APA 2000) 
and the National Institute of Neurologic, Communicative 
Disorders and Stroke-AD and Related Disorders Asso-
ciation (NINCDS-ADRDA) (McKhann et al 1984) are the 
most commonly used diagnostic criteria to deﬁ  ne AD. The 
NINCDS-ADRDA further divides a diagnosis of AD into 
three distinct categories: deﬁ  nite (clinical diagnosis with 
histologic conﬁ  rmation), probable (typical clinical syndrome 
without histologic conﬁ  rmation), and possible (atypical 
clinical features, no alternative diagnosis, no histologic 
conﬁ  rmation). Currently, postmortem histological examina-
tion of cortical tissue is the only way to establish a deﬁ  nite 
diagnosis of AD.
The prognosis of AD is continual neural degeneration 
with an increase in the range and severity of cognitive Neuropsychiatric Disease and Treatment 2008:4(4) 767
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impairment as the disease progresses (Cummings 2004; 
Husain and Garrett 2005). A recent study by Larson and 
colleagues (2004) found that the median survival rate 
following initial diagnosis of AD was 4.2 years for men and 
5.7 years for women. The Alzheimer’s patients in this study 
were found to have a decreased survival rate compared to 
the life expectancy of the general US population. Although 
there is currently no cure or method of preventing AD, 
some limited treatment options are available. The goals 
of current treatments are to reduce the severity or slow 
the progression of the cognitive and behavioral symptoms 
associated with AD (Clark and Karlawish 2003; Farlow 
2007). The aim of future treatments under investigation 
will be to inhibit the progression of the illness or even 
prevent the onset of AD. This review will describe the 
safety and efﬁ  cacy of these current therapeutic treatments 
and discuss the current state of various disease-modifying 
treatments.
Current treatments for Alzheimer’s 
disease
Cholinesterase inhibitors
The brains of patients with Alzheimer’s have been found 
to have reduced cholinergic activity (Davies and Maloney 
et al 1976; Perry et al 1977). It has been suggested that this 
decrease in cholinergic activity is related to the cognitive 
symptoms of AD; therefore, enhancing the remaining 
acetylcholine is believed to improve cognition. The ﬁ  rst 
class of drugs introduced to treat Alzheimer’s is referred 
to as acetylcholinesterase or cholinesterase inhibitors, 
and are characterized as a symptomatic treatment. 
Cholinesterase inhibitors are able to prolong the action of the 
neurotransmitter acetylcholine by reducing its metabolism 
at the synaptic cleft. The first cholinesterase inhibitor 
approved by the Food and Drug Administration (FDA) for 
the treatment of Alzheimer’s was tacrine. This treatment 
was able to slow the progression of cognitive deterioration 
in AD patients; however, the clinical signiﬁ  cance was not 
well established (Qizilbash et al 2000). Tacrine is now 
rarely used because of the increased risk of hepatoxicity, 
and the development of safer cholinesterase inhibitors. 
The three commonly used cholinesterase inhibitors, which 
are approved by the FDA for the treatment of Alzheimer’s, 
include donepezil, galantamine, and rivastigmine. All of 
these cholinesterase inhibitors have been shown to improve 
cognition over placebo conditions (Ritchie et al 2004), and 
they have been found to delay cognitive impairment for up 
to 6-months in patients with mild to moderately severe AD 
(Takeda et al 2006).
Donepezil
Donepezil (Pﬁ  zer Inc., NY, USA) is a selective acetylcholine 
inhibitor which has been shown to reduce the progression 
of atrophy in the hippocampus (Hashimoto et al 2005), and 
signiﬁ  cantly improve Clinician’s Interview Based Impres-
sion of Change-plus (CIBIC-plus) scores for patients with 
moderate to severe AD, relative to placebo (Feldman et al 
2005). The CIBIC-plus is a global scale used to assess clini-
cal status that involves a semi-structured interview with the 
patient and caregiver. Donepezil also demonstrated signiﬁ  -
cant improvement on the Alzheimer’s Disease Assessment 
Scale-Cognition (ADAS-cog) (Birks and Harvey 2006), a 
scale used to assess cognitive functioning in patients with 
AD, as well as a delayed decline in the ability of patients 
with AD to perform various activities of daily living (ADL). 
A study by Feldman and colleagues (2003) that provided 
donepezil daily for 24-weeks to patients with moderate to 
severe AD demonstrated a slower decline in instrumental 
and basic ADLs compared to placebo. The reduction in the 
decline of patients’ ability to perform ADLs was also related 
to a decrease in stress of the caregivers. Data has indicated 
patients with mild to moderate AD who delay treatment will 
not receive full beneﬁ  t of donepezil, and thus treatment with 
that medication should be initiated early in the course of AD 
(Winblad et al 2006).
Rivastigmine
Rivastigmine (Novartis Pharmaceuticals Corporation, NJ, 
USA) is a dual acting inhibitor that targets both acetyl-
cholinesterase and butyrylcholinesterase. Treatment with 
rivastigmine has been shown to provide therapeutic beneﬁ  t 
for cognitive symptoms associated with AD. A study by Alm-
kvist and colleagues (2004) compared the cognitive outcome 
of patients with mild AD receiving treatment with rivastig-
mine for 12 months to untreated patients with Alzheimer’s or 
mild cognitive impairment (MCI). The results of the patients 
with AD indicated treatment with rivastigmine was able to 
maintain or minimally improve cognition, compared to a 
marked decline in cognition for those patients with AD not 
receiving treatment. Another study, which included patients 
with moderately severe AD also found rivastigmine to pro-
vide symptomatic beneﬁ  t for cognitive impairment (Burns 
et al 2004). Patients receiving 6–12 mg/day of rivastigmine 
for 6 months demonstrated a slight improvement on the 
ADAS-cog, compared to a decline for patients receiving Neuropsychiatric Disease and Treatment 2008:4(4) 768
Husain et al
placebo. In addition to providing improvement in cognition, 
rivastigmine may help improve or prevent psychotic and 
nonpsychotic symptoms that are associated with Alzheimer’s. 
A review of double-blind randomized trials, which supported 
the beneﬁ  cial effect of rivastigmine on cognitive function-
ing, also demonstrated improvement in activities of daily 
living (Birks et al 2000). Meta-analytic data, which included 
three placebo-controlled studies, suggested that treatment 
with 6–12 mg/day of rivastigmine could potentially reduce 
or prevent dementia related behavioral and psychological 
symptoms (Finkel 2004).
Galantamine
The drug galantamine (Orth-McNeil Neurologics Inc., NJ, 
USA) is a unique cholinesterase inhibitor that in addition to 
prolonging the action of the neurotransmitter acetylcholine, 
is able to allosterically modulate nicotinic acetylcholine 
receptors which potentate the response of these receptors 
to acetylcholine (Scott and Goa 2000; Maelicke et al 2001). 
A 6-month, randomized, controlled trial of galantamine 
found patients with mild to moderate AD who received 
doses of 24 mg/d or 32 mg/d had signiﬁ  cantly improved 
cognitive abilities compared to patients who received placebo 
(Raskind et al 2000). Patients who received active treatment 
at either dose showed superior scores on both the CIBIC-plus 
and the 11-item ADAS-cog subscale. Similar results were 
also indicated in the Cochrane Review (Loy and Schneider 
2006), which consisted of ten double-masked, randomized 
controlled trials. The review concluded that 16 mg/d to 
24 mg/d of galantamine provided improvement in global and 
cognitive symptoms for at minimum 6 months. Regarding 
the long term therapeutic beneﬁ  t of galantamine, patients that 
continued to receive 24 mg/d for an additional 6 months were 
able to maintain cognitive and daily functioning (Raskind 
et al 2000). The ability to maintain cognitive functioning was 
also demonstrated in an observational study that followed 
patients with mild to moderate AD who were treated with 
galantamine for a period of 6-months (Brodaty et al 2006). 
Although galantamine has a dual mechanism of action, it has 
not been shown to provide signiﬁ  cant beneﬁ  t over donepezil 
(Harry and Zakzanis 2005).
Summary of cholinesterase inhibitors
All three currently approved cholinesterase inhibitors have 
demonstrated modest symptomatic benefit, and despite 
variation in their mechanisms of action, there appears to 
be no difference in their respective efﬁ  cacy (Birks 2006; 
Takeda et al 2006). In general, cholinesterase inhibitors 
are well tolerated; however, various gastrointestinal side 
effects, such as diarrhea, nausea, and vomiting are common 
and can reduce treatment compliance. Rivastigmine has a 
recently FDA-approved skin patch that has been shown to 
eliminate gastrointestinal side effects (Winblad et al 2007). 
These drugs should be used judiciously with patients that 
have cardiac problems, bladder outﬂ  ow obstruction, seizures, 
active peptic ulcer disease, or asthma. Refer to Table 1 for 
additional information concerning each FDA-approved cho-
linesterase inhibitor. All of these cholinesterase inhibitors 
have been found to slow the progression of AD, but none 
have resulted in signiﬁ  cant cognitive improvement over a 
period of time. Also, if these cholinesterase inhibitors are 
acutely discontinued, there is then a high risk of expedited 
decline in cognitive functions.
NMDA receptor modulator: Memantine
Another FDA-approved treatment for AD is memantine (For-
est Laboratories Inc., Titusville, NJ, USA) which provides 
neuroprotection against Alzheimer’s pathology. Memantine 
is an antagonist of the N-methyl-D-aspartate (NMDA) recep-
tor that interferes with glutamate, a neurotransmitter believed 
to overstimulate the NMDA receptors in AD, causing neu-
ronal death and subsequent cognitive impairment (Lipton 
and Rosenberg 1994). A randomized, double-masked trial 
of memantine found that patients with moderate to severe 
AD receiving 20 mg/day for 28 weeks had a better outcome 
relative to patients receiving placebo (Reisberg et al 2003). In 
addition to the reduction in clinical deterioration which was 
evident in the CIBIC-plus and ADL Inventory, memantine 
was well tolerated, as substantiated by a lower discontinuation 
rate than the placebo group. Another study reported signiﬁ  cant 
reduction in nursing time, extended time to institutionaliza-
tion, and maintenance of autonomy relative to a placebo 
condition (Heinen-Kammerer et al 2006). Memantine’s 
therapeutic beneﬁ  t in cognition and delay in functional decline 
was also demonstrated in a review of additional randomized 
controlled studies (McShane et al 2006).
Various randomized controlled trials of memantine have 
shown less reported agitation in patients with moderate to 
severe AD receiving memantine, compared to those receiving 
a placebo (Reisberg et al 2003; Gauthier et al 2005; van Dyck 
et al 2007). In regards to safety, a review by Robinson and 
Keating (2006) indicated the only side effects that occurred at 
a higher rate over placebo were dizziness, headache, constipa-
tion, and somnolence. Memantine has been shown to work 
in combination with the cholinesterase inhibitor donepezil. 
This combination resulted in signiﬁ  cantly better outcomes on Neuropsychiatric Disease and Treatment 2008:4(4) 769
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various measures over placebo; however, additional research 
is required to determine the long term beneﬁ  t of this medi-
cation combination (Tariot et al 2004). Refer to Table 1 for 
additional information regarding memantine.
Non-FDA-approved Alzheimer’s disease 
treatments
Although donepezil, galantamine, rivastigmine, and meman-
tine are the only FDA-approved treatments for AD, various 
other agents have been suggested to treat Alzheimer’s. Past 
studies found patients who reported a higher use of nonste-
roidal antiinﬂ  ammatory drugs (NSAIDs) were less likely to 
develop AD compared to patients with less frequent NSAID 
use (McGeer et al 1996; Stewart et al 1997). Although these 
ﬁ  ndings suggested that NSAIDs may have neuroprotective 
properties against the development of AD, recent double-
masked, placebo controlled trials have failed to demonstrate 
any therapeutic beneﬁ  t in the development of AD (Aisen et al 
2003; ADAPT Research Group 2007).
The use of estrogen during hormone-replacement therapy 
(HRT) has also been posited as a neuroprotective treatment 
for AD. Studies that reviewed the effect of HRT found a 
decreased risk in the development of dementia (LeBlanc et al 
2001; Nelson et al 2002). Although these ﬁ  ndings were prom-
ising, randomized double-masked, placebo-controlled trials 
of estrogen failed to ﬁ  nd any signiﬁ  cant beneﬁ  t for patients 
with mild to moderate AD (Henderson et al 2000; Mulnard 
et al 2000; Wang et al 2000). A study by Shumaker and col-
leagues (2003) even found postmenopausal women that were 
treated with estrogen plus progestin had an increased risk for 
dementia. The use of HRT in women is not currently recom-
mended as a treatment for the maintenance or improvement 
of cognitive functioning in AD (Hogervorst et al 2002).
Agents that are able to protect against oxidative damage 
have been found to serve as a neuroprotective treatment 
against Alzheimer’s. Sano and colleagues (1997) conducted 
a randomized controlled trial that contrasted the effect of 
10 mg/d of selegiline, 2000 IU/d of vitamin E, or both 
selegiline and vitamin E to a placebo condition in patients 
with moderate AD. After adjusting for differences in the 
baseline Mini Mental State Examination (MMSE) scores 
for the treatment and placebo groups, a signiﬁ  cant decrease 
in the progression of AD was indicated for those receiv-
ing active treatment. There was no statistically signiﬁ  cant 
difference between the three treatment groups. The results 
from this study did support the use of vitamin E as a neu-
roprotective treatment for Alzheimer’s; however, not all 
randomized control trials have been able to demonstrate a 
beneﬁ  t. A randomized trial that compared vitamin E to the 
cholinesterase inhibitor donepezil in the treatment of patients 
with MCI found no beneﬁ  t for patients receiving vitamin E 
(Petersen et al 2005). Patients that received donepezil had a 
Table 1 Summary of FDA-approved medications for AD
Donepezil Galantamine Rivastigmine Memantine
Dose 5 mg/d for 30 days, 
then 10 mg/d.
4 mg bid for 30 d, then 
16 mg bid, then 24 mg 
bid.
1.5 mg bid for 14 d, then 3 mg 
bid for 14 d, then 4.5 mg bid 
for 14 d, then 6 mg bid.
5 mg/d for 7 d, then 5 mg 
bid for 7 d, then 10 mg 
in AM 5 mg QHS for 7 d, 
then 10 mg bid.
Mechanism of action Acetyl cholinesterase 
inhibitor
Acetyl cholinesterase 
inhibitor, also modulates 
nicotinic receptors
Acetyl cholinesterase and 
butyl cholinesterase inhibitor
N-methyl-D-aspartate 
receptor modulator
Indication Mild, moderate, severe 
AD
Mild-moderate AD Mild-moderate AD Moderate-severe AD
Absorption affected 
by food
No Yes Yes No
Protein binding 96% 0%–20% 40% 45%
Common side effects Nausea, vomiting, 
diarrhea
Nausea, vomiting Nausea, vomiting, weight loss, 
anorexia
Hallucination, confusion, 
dizziness, headache
Serum half life 70–80 hrs. 5–7 hrs. 2 hrs. 45 hrs.
Metabolism CYP2D6, CYP3A4 CYP2D6, CYP3A4 Nonhepatic Nonhepatic
Other concerns Few drug-drug 
interaction
Renal impairment 
increases serum level, 
paroxetine/ketoconazole 
increases serum level
Renal impairment increases 
serum level
Alkalinzation of urine to 
pH of 8 lessens clearance
Abbreviation: AD, Alzheimer’s disease.Neuropsychiatric Disease and Treatment 2008:4(4) 770
Husain et al
decreased rate in the development of Alzheimer’s compared 
to those receiving placebo or vitamin E. Additional research 
is warranted to determine whether cholinesterase inhibitors 
and antioxidants, such as vitamin E, provide any signiﬁ  cant 
beneﬁ  t in the prevention and treatment of AD.
Future disease modifying therapies 
for Alzheimer’s disease
Unfortunately, the currently approved treatments for AD 
described above only work to slow the progression of the 
illness or treat its symptoms. The goals for future disease 
modifying treatments will include halting the progression 
of the illness, reversing the physical and cognitive effects 
associated with the illness, and delaying or even preventing 
its occurrence. There are certain areas of interest in which 
various treatment strategies have been developed. The main 
areas of interest have involved the two pathophysiological 
hallmarks of AD, which are the neuritic plaques that consist 
of Aβ proteins and the neuroﬁ  billary tangles.
The leading hypothesis indicates that the Aβ peptides are 
what lead to the overall pathology of AD (Hardy and Selkoe 
2002; Klafki et al 2006; Christensen 2007). These peptides 
are fragments of a transmembrane protein referred to as the 
amyloid precursor protein (APP) (Bayer et al 2001). During 
metabolism of this protein, enzymes referred to as β-secretase 
and γ-secretase cleave APP at speciﬁ  c regions, which produce 
the fragments or monomers that constitute Aβ (Walter et al 
2001). The initial cleavage of APP occurs outside the cell 
by β-secretase, while γ-secretase completes the cleavage 
in the cell membrane (Masters et al 2006). Therefore, the 
majority of research has focused on decreasing Aβ produc-
tion, limiting Aβ aggregation, or clearing existing Aβ from 
the brain. Although less attention has been provided to the 
neuroﬁ  billary tangles, methods for reducing or preventing 
their development have also been examined.
Treatments based on the Aβ theory
Removing the existing Aβ
Because the neuritic plaques seen in AD lead to the over-
all pathology of the disease and accumulate many years 
before the onset of symptoms, treatments specifically 
designed to remove existing Aβ plaques or reduce high 
levels of Aβ peptides are of considerable interest. Increas-
ing the expression of certain Aβ degrading enzymes such 
as neprilysin (NEP) and insulin-degrading enzyme (IDE), 
have been suggested as potential methods of reducing the 
level of existing Aβ levels (Eckman and Eckman 2005). A 
study using AD transgenic mice that had an over expression 
of IDE or NEP demonstrated a signiﬁ  cant reduction in Aβ 
levels, which also reduced the development of additional 
AD pathology (Leissring et al 2003). The authors of this 
study suggested that reducing the level of Aβ monomers 
might allow another endogenous mechanism to clear exist-
ing plaques. However, a recent study using elderly AD 
transgenic mice that had already developed plaques found 
that increased NEP levels did not reduce existing plaques 
(Mohajeri et al 2004). The use of Aβ-degrading enzymes as 
a treatment for AD will most likely be used in combination 
with other therapies that can effectively dissolve existing 
plaque formation.
Another strategy to clear existing Aβ currently in devel-
opment is immunotherapy with active and passive vaccina-
tion against Aβ. The use of active immunization for Aβ has 
been shown to prevent the formation of plaques in young 
transgenic mice, as well as reduce the progression of AD 
like pathology in older mice that had already developed Aβ 
plaques (Schenk et al 1999). The vaccine AN-1792 reached 
phase II clinical trials; however, the study was halted after 
18 of the 298 (6%) patients that were vaccinated developed 
meningoencephalitis (Orgogozo et al 2003). Although the 
study was halted, initial data suggested that the vaccine was 
effective. Following histology of patients that received AN-
1792, signiﬁ  cant clearance of Aβ plaques was discovered 
(Nicoll et al 2003; Ferrer et al 2004; Masliah et al 2005) 
and patients that developed Aβ antibodies demonstrated 
an improvement in memory and cognition (Gilman et al 
2005; Hock et al 2003). These results from AN-1792 were 
interesting, but due to the risk of developing meningoen-
cephalitis, which may have been related to incidental T-cell 
activation, the present focus turned to the use of passive 
immunization.
Passive immunization involves the direct transfer of 
Aβ antibodies that can decrease existing plaque formations. 
Intravenous immunoglobulin preparations (IVIgG) have been 
found to contain naturally occurring Aβ antibodies which 
might be able to clear existing Aβ plaques (Du et al 2003). 
Preliminary data of the efﬁ  cacy of IVIgG was examined in a 
small clinical trial that provided treatment (once every four 
weeks for up to 6 months) to 5 patients with AD (Dodel 
et al 2004). At completion of the trial, a 30.1% reduction of 
Aβ levels in cerebrospinal ﬂ  uid was detected with minimal 
change in performance on cognitive measures. These results 
indicate the need for a large scale study to adequately deter-
mine the clinical beneﬁ  t of this treatment.
Alternative passive immunizations for AD, such as 
humanized monoclonal antibodies, include bapineuzumab Neuropsychiatric Disease and Treatment 2008:4(4) 771
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(AAB-001) and LY2062430. A phase II trial of AAB-001 
was recently completed, and though results are not expected 
until late 2008, the manufacturers of the drug have announced 
they intend to proceed with a phase III clinical trial (Samson 
2007). LY2062430 is a version of the m266 antibody that 
has been shown to reverse memory deﬁ  cits in animal models 
(Dodart et al 2002), and is presently in phase II trials (Eli 
Lilly, Indianapolis, IN, USA). Passive immunotherapy does 
represent a safer strategy relative to active immunization. 
Nonetheless, the exact mechanism of action of Aβ immuno-
therapy is still unknown, which makes development of any 
AD immunotherapy difﬁ  cult.
Limiting the aggregation of Aβ
A review by Walsh and Selkoe (2004) suggested that the 
accumulation of Aβ is the event that leads to the overall 
pathophysiology of AD, which is directly related to the 
memory impairment associated with the disease. After the 
Aβ fragments are produced via the cleavage of APP, they 
begin grouping together, at which point they are believed to 
produce a neurotoxic effect (Masters et al 2006). Treatments 
designed to prevent the aggregation of Aβ into plaques are 
currently being developed. For example, the drug tramipro-
sate (3-amino-1-propanesulfonic acid) is a compound that has 
been shown to bind and prevent the aggregation of soluble 
Aβ in transgenic mice (Gervais et al 2007). According to 
a recently published report, a phase III clinical trial of tra-
miprosate in 1052 patients with mild to moderate AD has 
recently been completed, although the results have yet to be 
published (Aisen et al 2007).
Iodochlorhydroxyquin (clioquinol) is another drug that 
has demonstrated antiaggregate properties on Aβ. The metal 
ions copper, zinc, and iron have been found to mediate the 
aggregation and neurotoxicity of Aβ (Rogers and Lahiri 
2004). Chelating agents like clioquinol binds with zinc and 
copper ions, and has been found to reduce the accumulation 
of Aβ in transgenic mice (Cherny et al 2001). A pilot phase II 
clinical trial of clioquinol demonstrated a decrease in the Aβ 
levels, compared to an increase found in the placebo group 
(Ritchie et al 2003). The drug was also well tolerated. It must 
be noted that the results of this study are limited because of 
the small sample size, which included 36 patients with AD 
with 18 receiving active medication and 18 receiving pla-
cebo. A drug that has been shown to bind to iron ions is the 
monoamine oxidase inhibitor M-30. Within a cellular model, 
this drug has been shown to regulate APP and Aβ levels, thus 
it may be able to treat various neurodegenerative disorders, 
including Alzheimer’s (Avramovich-Tirosh et al 2007).
NC-531 is a treatment that is currently in phase III clinical 
trials (Geerts 2004). NC-531 interacts with the metabolism 
of Aβ and prevents the formation of plaques. In the phase II 
trial, which included 58 patients with mild AD, there was a 
70% reduction in Aβ levels. A review of disease modifying 
Alzheimer’s treatments suggest that aggregation inhibitors 
that are peptide based may be the most effective as they 
interact with broader regions of the Aβ peptide and have been 
shown to disaggregate existing Aβ ﬁ  brils (Golde 2006).
Decreasing the production of Aβ
Reducing the generation of Aβ through the regulation or 
modulation of certain secretases responsible for its produc-
tion represents another novel treatment strategy (Aisen 2005; 
Hamaguchi et al 2006). β-secretase inhibitors have been 
studied as a potential method for the prevention and treatment 
of AD. Data from animal models have demonstrated that 
knockout mice lacking the β-secretase enzyme responsible 
for the extracellular cleavage of APP have limited Aβ produc-
tion (Cai et al 2001; Luo et al 2001). Inhibiting β-secretase 
is considered a safe treatment strategy; however, additional 
research is still needed to substantiate that claim. Data from 
animal studies targeting β-secretase have demonstrated an 
increased neonatal mortality rate as well as additional cogni-
tive deﬁ  cits suggesting this strategy may produce unintended 
adverse events (Dominguez et al 2005; Laird et al 2005).
The results from a new β-secretase inhibitor (KMI-429) 
have been more promising in reducing Aβ production in 
laboratory and wild type mice, without the development 
of any apparent adverse events (Asai et al 2006). Although 
the data from these animal studies have been encouraging, 
creating an effective β-secretase inhibitor with good oral 
bioavailability has proven to be a great challenge. Current 
compounds that are capable of inhibiting β-secretase are 
too large to cross the blood-brain barrier, while smaller 
compounds that can cross have lacked efﬁ  cacy (Dewachter 
and Van Leuven 2002; Citron 2004).
Inhibiting the γ-secretase, the enzyme responsible for the 
second cleavage of APP, is another method to reduce the 
production of Aβ. Animal models have demonstrated that 
γ-secretase inhibitors are capable of reducing the level of 
Aβ peptides (Dovey et al 2001; Wong et al 2004; Barten 
et al 2005). A phase I study of the γ-secretase inhibitor 
LY450139 found that participants who were administered 
40 mg for 14 days experienced manageable side effects such 
as headaches, myalgia, and pain, which were also reported 
in the placebo group (Siemers et al 2005). A reduction in 
Aβ concentration was also noted, and was found to be dose Neuropsychiatric Disease and Treatment 2008:4(4) 772
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dependent. Another phase II trial of LY450139 indicated 
an Aβ reduction of 58.2% and 64.6% for those receiving 
100 mg and 140 mg respectively (Eastman 2007). Another 
γ-secretase inhibitor that has shown promise is MK-0752 
(Rosen et al 2006). A single dose ranging from 110 mg to 
1000 mg was well tolerated by 27 healthy participants, and 
signiﬁ  cant reduction in Aβ was observed. Although the data 
from these initial trials of γ-secretase inhibitors are promising, 
these studies had relatively small sample sizes which limited 
the generalizability of their safety and efﬁ  cacy. A review 
by Barten and colleagues (2006) illustrated that γ-secretase 
inhibition produced abnormalities in the gastrointestinal 
tract, thymus, and spleen in animals, which indicates further 
safety testing is necessary before beginning phase II trials. A 
feasible substitute to inhibiting the γ-secretase enzymes may 
be to modulate its effect on the amyloid precursor protein. 
Modulation of the γ-secretase enzyme can also be achieved 
by the use of NSAIDs, which moves the γ-secretase cleav-
age to a shorter Aβ peptide reducing the production of Aβ42 
(Eriksen et al 2003). R-Flurbiprofen (Flurizan™) is a NSAID 
derived modulator that is currently in phase III development 
(Golde 2006). Results from the phase II trial of Flurizan 
demonstrated that it was well tolerated and showed signiﬁ  cant 
beneﬁ  t for patients with mild AD by improving activities of 
daily living and global function (Black et al 2006).
The α-secreatase is another enzyme that cleaves the APP; 
however, this cleavage occurs between the Aβ sequence 
which prevents the production of the Aβ fragment responsible 
for the development of the neurotoxic plaques present in 
AD (Walter et al 2001; Aisen 2005). Activators of the 
α-secretase can possibly increase this type of passive cleavage 
of APP and reduce Aβ production. Transgenic mice that 
have an overexpression of disintegrin and metalloprotease-
10 (ADAM-10), which activates α-secretase, demonstrated 
a decrease in Aβ peptide production and prevented the 
formation of amyloid plaques (Postina et al 2004). Although 
it may be possible to suppress Aβ production by way of 
inhibition, modulation, or activation of speciﬁ  c protease 
secretases, data suggests preventing Aβ production would be 
unable to effectively breakup Aβ that have already aggregated 
(Jankowsky et al 2005).
Research has also suggested that tumor necrosis factor-
α (TNF-α), a proinﬂ  ammatory cytokine, may play a role 
in the development of AD by initiating an inﬂ  ammatory 
immune response affecting the brain (Perry et al 2001). An 
open-label, proof of concept study with the TNF-α inhibi-
tor, etanercept, demonstrated improvement on all primary 
efﬁ  cacy measures after 6 months of weekly treatment with 
25 to 50 mg (Tobinick et al 2006). The data from this study 
is encouraging; however, large scale, randomized, double-
masked trials are needed.
Treatments based on tau pathology
Preventing the aggregation of tau
In addition to the development of treatments that target Aβ 
aggregation, treatments that are capable of targeting neuroﬁ  -
brillary tangles are also needed to stop the progression of the 
illness. The majority of treatments that target tau pathology 
have focused on the hyperphosphorylation and aggregation 
of tau proteins. The hyperphosphorylation of tau proteins in 
AD may be related to an enzyme called glycogen synthase 
kinase 3β (GSK-3β) (Johnson and Hartigan 1999), which can 
be activated by aggregates of Aβ peptides (Hoshi et al 2003). 
Recent studies using cell models demonstrated that certain 
drug inhibitors are able to prevent tau protein aggregation 
and even dissolve the aggregates that have already developed 
(Khlistunova et al 2006; Masuda et al 2006). Although these 
initial ﬁ  ndings are promising, in vivo studies are still needed to 
demonstrate efﬁ  cacy and safety of tau aggregate inhibitors.
Preventing the phosphorylation of tau
Preventing the hyperphosphorylation of tau proteins, which is 
believed to result in tau aggregation, is another strategy under 
investigation. The phosphorylation of tau is controlled in part 
by glycogen synthase kinase 3β (GSK-3β), and it has been 
suggested that inhibiting GSK-3β may prevent the formation 
of tangles (Bhat et al 2004; Balaraman et al 2006). The M1 
muscarinic agonist AF267B (also referred to as NGX267) 
has been shown to inhibit GSK-3β activity and reduce tau 
pathology in transgenic mice (Caccamo et al 2006). Lithium has 
also been suggested as a GSK-3β inhibitor; however, data from 
a study by Dunn and colleagues (2005) failed to demonstrate a 
protective response to lithium against the development of AD. 
Two additional inhibitors of tau hyperphosphorylation that 
have shown modest success in transgenic mouse models are 
propentofylline (PPF) and SRN-003-556. Although the exact 
mechanism of PPF is unknown, it reduced the active form 
of GSK-3β and prevented the hyperphosphorylation of tau 
proteins (Chauhan et al 2005). SRN-003-556 was able to reduce 
soluble tau proteins that were hyperphosphorylated; however,
no change was evidenced in existing neuroﬁ  brillary tangles 
(Le Corre et al 2006).
Activating tau chaperones
In addition to tau aggregation, the misfolding of hyperphos-
phorylation tau proteins has also been suggested to contribute Neuropsychiatric Disease and Treatment 2008:4(4) 773
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to the intracellular pathology of AD (Golde 2006). Certain 
proteins are able to regulate and prevent improper folding of 
tau in order to avoid aggregation. The results from a study 
by Dou and colleagues (2003) suggested that increasing the 
activation of molecular chaperones might prevent the mis-
folding of tau, which would then reduce the development 
of neuroﬁ  brillary tangles. Heat shock proteins have been 
shown to activate chaperones that prevent misfolding and 
even promote tau binding with microtubules (Petrucelli et al 
2004; Dickey et al 2006). Additional research is required to 
determine whether targeting tau chaperones would be able 
to produce signiﬁ  cant beneﬁ  t in humans.
Treatments based on neuroprotection
Treatment strategies that promote neuronal protection from 
the pathophysiology associated with Alzheimer’s are cur-
rently being developed. Increasing the neurotrophic factors, 
nerve growth factor (NGF) and brain-derived neurotropic 
factor (BDNF), has been posited to enhance neural survival 
and improve cognition (Fumagalli et al 2006; Williams et al 
2006). The drug AIT-082 (Neotroﬁ  nTM), a purine derivative 
that enhances NGF, has been shown to improve working 
memory in mice (Glasky et al 1994). A phase I trial of AIT-
082 that included 36 patients with AD, found it to be a safe 
and well tolerated treatment at doses of 100 mg, 500 mg, 
and 2000 mg a day (Grundman et al 2003). Neuroprotec-
tive agents may be able to help reduce further degeneration, 
although it is unknown whether this would have a large 
enough effect on the overall pathology of AD. The glucocor-
ticoid antagonist mifepristone has recently been suggested 
as a neuroprotective treatment for AD (Dhikav and Anand 
2007). Stress has been suggested as a factor that contributes 
to the development of Alzheimer’s (Miller and O’Callaghan 
2005); therefore, inhibiting glucocorticoid may help protect 
against AD-related cellular degeneration. Additional research 
is needed to determine whether any effect would be clini-
cally signiﬁ  cant.
Discussion
Signiﬁ  cant progress has been made in the understanding 
of the overall course of AD, from the progression of the 
pathophysiology to the onset of clinical symptoms. This 
understanding has led to the development of current 
Alzheimer’s treatments which are able to slow the progression 
of the cognitive symptoms, and modestly control certain 
behavioral symptoms. These current treatments mainly use 
symptomatic treatment strategies. Increasing neuroprotection 
against existing Aβ plaques and neuroﬁ  brillary tangles can 
help slow the progression of the illness, but current treatments 
are unable to clear existing or prevent the formation of 
new Aβ plaques. Another limitation of current treatments 
involves their inability to reverse existing neuronal damage. 
The pathology of AD is believed to occur years before the 
manifestation of clinical symptoms signiﬁ  cant enough to 
indicate a diagnosis of AD; therefore, drugs that are able to 
reverse the neurodegeneration are warranted. True disease-
modifying therapies are currently being developed to address 
these limitations.
The goal of future AD treatments will be to inhibit the 
progression of the illness and reverse its pathology, with the 
hope of returning cognitive functioning that was previously 
lost. Because it is currently believed that the pathogenesis 
of AD is related to the accumulation of a 40–42-amino-
acid referred to as Aβ, the majority of treatment strategies 
have targeted Aβ production and aggregation. Drugs that 
either inhibit β-and γ-secretase or activate α-secretase have 
demonstrated the ability to decrease production (Cai et al 
2001; Postina et al 2004; Wong et al 2004; Barten et al 2005; 
Siemers et al 2005), while other drugs have been able to 
prevent the aggregation of existing Aβ peptides (Gervais et al 
2007; Cherny et al 2001; Ritchie et al 2003; Avramovich-
Tirosh et al 2007).
Although these strategies are promising, treatments 
capable of targeting existing Aβ plaques are also in devel-
opment. Immunotherapy involving active immunization 
demonstrated initial success in animals (Schenk et al 1999), 
but due to side effects reported during the phase II trial of 
AN-1792 (Orgogozo et al 2003), attention has now turned to 
passive immunization. The passive immunization treatment 
AAB-001 recently completed a phase II trial, and will soon 
begin a phase III efﬁ  cacy trial. The treatment strategies that 
target tau pathology mainly involve preventing hyperphos-
phorylation, misfolding, and aggregation of tau proteins. The 
data from cell and animal models have shown promise in 
reducing tau pathology (Khlistunova et al 2006; Masuda et al 
2006; Balaraman et al 2006; Caccamo et al 2006; Chauhan 
et al 2005; Dickey et al 2006), but compared to Aβ based 
treatments, less has been accomplished. If the progression of 
the illness is caused by the accumulation of Aβ, then targeting 
it could help prevent AD. However, because the neurodegen-
eration is also related to the neuroﬁ  brillary tangles, treatments 
designed to target tau pathology will be needed.
The difﬁ  culty in developing disease-modifying treatments 
is based on many factors including incomplete understanding 
of AD etiology, drug development, adequate trial design, 
and the associated cost of conducting these trials. Although Neuropsychiatric Disease and Treatment 2008:4(4) 774
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a great deal has been learned regarding the pathology of AD, 
its etiology remains unclear. Treatments can be developed 
to target speciﬁ  c stages in the illness, but without a clear 
understanding of the etiology of AD, it is difﬁ  cult to know 
which treatments would have a signiﬁ  cant and long lasting 
effect. Even with the knowledge of what stage in the illness 
to target, the regular difﬁ  culties in drug development are 
still present. An Alzheimer’s drug treatment has to be able 
to cross the blood brain barrier, perform a speciﬁ  c task, and 
produce minimal signiﬁ  cant side effects which would negate 
the beneﬁ  t of the treatment. The demands of conducting 
an adequate clinical trial for disease-modifying therapies 
are substantial in terms of duration and cost, which should 
be at least 18 months or longer (Cummings 2006; Vellas 
et al 2007) with an estimated cost of $30 to 50 million 
(Melnikova 2007).
Another current limitation is the lack of a biological 
marker (biomarker) to accurately diagnosis Alzheimer’s and 
to serve as an end-point during trials of disease-modifying 
treatments. A biomarker is deﬁ  ned as a biological measure that 
is capable of determining normal or pathogenic processes, as 
well as a pharmacological response to a treatment intervention 
(Biomarkers Deﬁ  nitions Working Group 2001). Biomarkers 
could allow for early treatment intervention and as with 
most conditions, the sooner therapy is initiated, the better the 
prognosis. If AD is unidentiﬁ  ed until clinical symptoms are 
reported, then a signiﬁ  cant degree of pathology, which reduces 
the effectiveness of current treatments, has already developed. 
In addition to allowing for early initiation of treatment, 
biomarkers could reduce the number of participants required 
and strengthen the results of efﬁ  cacy trials. Because of the 
extensive range in symptom severity, insidious progression 
of the disease, and lack of certainty regarding the diagnosis, 
a large sample size of patients receiving long term treatment 
and monitoring is required to demonstrate efﬁ  cacy (Golde 
2006). Biomarkers could allow for more accurate enrollment 
of patients with dementia of the Alzheimer’s type and serve 
as a surrogate end-point to measure the therapeutic beneﬁ  t of 
a treatment. Various potential biomarkers such as proteins, 
genes, and structural changes seen through neuroimaging 
have shown promise; however, further research is still needed 
(Vellas et al 2007).
At this time, no treatment is available to halt the 
progressive neurodegenerative nature of AD. However, as 
research involving the etiology and pathology of the illness 
continues, so too will the development of future treatments. 
Adequate biomarkers have yet to be identiﬁ  ed, but their 
potential worth in clinical application and research trials is 
signiﬁ  cant enough to warrant prospective research regarding 
their development. Certain treatments have shown promise 
and through further investigation, their role in combating AD 
will become apparent. The development of combination or 
dual acting treatments, capable of targeting multiple aspects 
of AD pathology will most likely be needed to signiﬁ  cantly 
alter the progression of the disease.
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